Since its foundation, Bluefish has focused
on developing a modern product portfolio with a wide range of high
quality generic pharmaceuticals within all major therapeutic
Such as cardiovascular, the central nervous system, gastrointestinal, diabetes, oncology, dermatology, respiratory, inflammatory, genito-urinary, antifungal, antiviral, endocrinology, analgesic and antibiotics.
Bluefish long-term strategy is to expand the product portfolio of generic versions of blockbusters as well as to gradually offer a broader range of niche products within more narrow disease areas or to meet the demand for regional treatment principles.
The company currently has 84 products in its portfolio whereof 63 are launched and 21 products are in development or under registration.